Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
  • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Definitions

• the present invention relates generally to the field of drug formulation, and more specifically, but not exclusively, to ordered solid mixtures of particulate pharmaceutical carrier substances and smaller particles of at least one pbarmaceutically active substance or agent, said smaller particles adhering to the carrier substance particles.
• the invention also relates to pharmaceutical preparations produced from the ordered mixtures and to a method for producing such preparations. Furthermore, the invention also relates to the use of the ordered mixtures for the preparation of said pharmaceutical preparations.
• the active substance(s) is (are) distributed uniformly over the surfaces of readily dissolvable carrier particles, therewith enabling the therapeutically active substances to dissolve more quickly. Consequently, the active substances will dissolve more rapidly when administered and consequently act more quickly, in a highly advantageous manner.
• R s constitutes a measurement of the quantity of particulate therapeutically active agent which will adhere to the surfaces of the larger carrier particles.
• R s is defined as the ratio of the projected surface of the adherent particles to the total external surface area of the carrier particles.
• the carrier substance particles have a pharmaceutical disintegrant (or "explosive") embodied therein.
• This disintegrant is effective in causing the carrier particles to disintegrate and dissolve rapidly when coming into contact with water, so as to release the individual, mutually discrete primary particles of active substance.
• Figure 1 is a diagram which illustrates the dependency of the dissolution rate on the various values of the surface area ratio.
• Figure 2 illustrates a comparison made between the dissolution rates of earlier known mixtures and those of mixtures according to the present invention.
• Figure 3 shows the result of a further comparison test and is illustrative of the significance of the nature of the carrier.
• the carrier particles will suitably contain up to 25% by weight disintegrant, preferably up to 10% by weight. In practice, contents below 1% by weight have been found to give an excessively low effect and an optimum content would appear to be from about 5 to 10% percent.
• a suitable carrier particle size is from 50 to 1000 microns, and then preferably from 100 to 500 microns. Although particle sizes which lie outside the widest range can also be used, practical difficulties are experienced when formulating pharmaceutical preparations from particles having such sizes.
• the carrier substance used may be any substance which is acceptable pharmaceutically and which is highly soluble in water and can be formed into particles which embody or incorporate a disintegrant.
• carbohydrates such as mannitol and lactose, or pharmaceutically acceptable inorganic salts, such as sodium chloride, can be mentioned as examples.
• the carrier substances comprises a fragmentizing material.
• a fragmentizing material is meant a material which is readily crushed or broken up when a pharmaceutical composition is compacted into tablets, so as to expose further surfaces.
• the aforesaid mannitol and lactose have been found particularly suitable in this respect.
• the pharmaceutical disintegrant may comprise any substance which is known for this purpose by those skilled in this art.
• Particularly effective agents in this respect are those which swell drastically in water, through hydratization, and thus exhibit an increase in volume of up to 10-20 times their dry volume.
• examples of such agents are cellulose and starch derivatives in the form of water-insoluble, cross-linked polymers which swell markedly in water.
• Derivatives of polyvinylpyrrolidone are other examples of such agents.
• One particularly suitable disintegrant for use in accordance with the present invention is a modified cellulose gum which is highly swellable in water and which is retailed under the trade name Ac-Di-Sol by FMC Corporation, USA.
• Other types of disintegrant can also be used, "and the person skilled in this art will have no trouble in choosing a suitable agent for the purpose intended.
• the disintegrant can be embodied in the carrier particles in various ways.
• the finely divided carrier can be granulated together with finely divided disintegrant in a liquid which will not dissolve the disintegrant or cause it to swell.
• the dry constituents are first mixed together and the resultant mix is then moistened with a liquid, such as absolute ethanol, which will not dissolve the substances present or cause swelling.
• the mass is then granulated, for instance by pressing the moist mass through a filter cloth and then drying and grinding the mass.
• the moist mass can be dried immediately and then granulated.
• Another way is to dissolve the carrier substance in a solvent which will not dissolve the disintegrant or cause it to swell, and then to add the disintegrant to the solution.
• a suitable grain size fraction of carrier with disintegrant shall be prepared in a final stage, e.g. by passing the granulate through an appropriate screen or sieve.
• Examples of different kinds of active substance which have been found useable in accordance with the invention include benzodiazepines, ergotamine tartrate, isosorbide dinitrate and griseofulvin.
• This list of active substances is by no means complete, however, since there can be used any agent which can be finely divided and caused to adhere in finely divided form to the surfaces of the carrier particles.
• the advantages afforded by the invention are achieved primarily with the use of active substances which are not dissolved readily in water and with which the degree of solubility can be varied in dependence on the active substance used. It will be understood that the degree of solubility of the active substance places no limitation on the scope of the invention.
• the pharmaceutically active substances present in the preparations will suitably have a maximum particle size of about 24 microns, preferably not greater than about 10 microns.
• the active substances are caused to adhere to the carrier particles by dry mixing the ingredients together over a sufficiently long period of time.
• This time period can vary and when mixing the ingredients on a laboratory scale can be of the order of from 10 to 100 hours, depending specifically on the substances used and the details of the mixing process applied.
• the requisite mixing time will be much shorter, normally in the order of from 10 to 60 minutes.
• One of normal skill in this art will have no difficulty in determining a suitable mixing time for a given combination of active substances and carrier on the basis of simple routine experiments.
• the active substance and carrier particles it has been found suitable when mixing the active substance and carrier particles together, to add also a proportion of pure carrier particles whose particle size is of the same order as that of the active substance. This will further enhance the subsequent dissolution of the substance in water.
• This proportion of pure, finely divided carrier added during the mixing process may equal 100% by weight of the amount of active substance present, and is suitably about k0% by weight.
• This additional carrier may comprise the same substance as that of the carrier which embodies the disintegrant, or may comprise another pharmaceutically acceptable carrier substance.
• the value obtained with the surface area ratio defined in the aforegoing is significant with respect to the amount of pharmaceutically active substance which shall adhere to the surfaces of the carrier particles.
• the surface area ratio will preferably not be greater than about 0.5.
• a ratio of this value will afford significant improvements with respect to dissolution rate in comparison with similar preparations which have the same surface area ratio, but with which the carrier particles lack the inclusion of a disintegrant. Improvements on preparations which lack the inclusion of a disintegrant in the carrier particles, but which are similar in other respects, will also be achieved at higher surface area ratio values. The improvements achieved in this latter case, bowever, are not so pronounced in the former case and are therefore of less practical importance.
• the ordered mixtures prepared in accordance with the invention can be incorporated in various kinds of pharmaceutical preparations. Such preparations are preferably intended for enteral administration, primarily orally.
• the preparations will then, for instance, be in the form of tablets, capsules, powders or granulates, or in the form of suppositories for rectal administration. It is also possible to use the ordered mixtures of the present invention in certain preparations or medica materia intended for external application, such as ointments and creams. Irrespective of the form given to the preparation, it is important that the preparation is essentially free from water, since the presence of water would result in premature dissolution of the active substance.
• the pharmaceutical preparations can be composed, by combining the inventive ordered mixtures with the conventional pharmaceutical additives and excipi ⁇ nts normally used in the desired forms of the preparations, with the aid of known methods herefor.
• Such additions may comprise, for instance, additional carriers, preservatives, lubricants, glidants, disintegrants, flavourants, dyestuffs and like substances, and are well known to the person skilled in this art.
• the disintegrant shall lie in the tablet between the mutually compacted carrier particles, active substance particles and particles of other substances present and contributes towards rapid disintegration of the tablet when the tablet is administered or taken.
• the disintegrant used in accordance with the present invention is embodied within the carrier particles and assists in causing the particles to dissolve rapidly.
• a final tablet composition will include both carrier particles which embody a disintegrant there-within and which have smaller particles of active substance adhering to the surfaces thereof and also a further disintegrant which is intended to exercise its conventional function.
• Example 1 This example illustrates the effect of the surface area ratio on the rate-of dissolution when using carrier particles which do not have a disintegrant embodied therein.
• Dry mannitol having a particle size of 250-450 microns was mixed dry with micronized oxazepam, the degree of fineness being such as to obtain an external specific surface area of not less than 20000 cm 2 /g, measured in accordance with a permeatric surface method.
• Surface area ratios of 0.08, 0.57 and 1,5 were obtained, corresponding to an oxazepam addition of 0.4% w/w, 2% w/w and 5% w/w respectively.
• the mixing time was about 50 hours.
• Each of the three ordered mixtures thus obtained was then divided into three parts.
• the dissolution rate of each of the mixtures having mutually different surface area ratio values was then investigated directly in accordance with U.S. P. XXI, pages 1243-1244, the paddle method, at room temperature and at a stirring or paddle speed of 100 rpm.
• each respective mixture was formulated into tablets, by admixing the ordered mixture with 5% w/w Avice R , PH 101 (trade name for microcrystalline cellulose) and 2% w/w Ac-Di-Sol (trade name for a modified cellulose gum of high water-swellability) over a time period of 30 minutes, and then compacting the resultant mixtures into tablets containing 2 mg oxazepam in the case of mixtures having a surface area ratio of 0.08 and 10 mg oxazepam in the case of mixtures having surface area ratios of 0.57 and 1.5 respectively.
• the mixtures were compacted at two mutually different pressures of 100 MPa and 200 MPa.
• the dissolution rate of these tablets was similarly investigated in accordance with U.S.P XXI, the paddle method, at room temperature and a stirring speed of 100 rpm.
• the curves also show that the dissolution rate decreased markedly in the case of mixtures having a surface area ratio of 0.57, and that a time period of about 30 minutes was needed to obtain near complete dissolution, as compared with a time period of about 2 minutes for the mixtures which had a surface area ratio of 0,08.
• the curves also show that initially the tablets dissolve more rapidly than the mixture alone.
• the dissolution rate has decreased so markedly as to render the mixture unusable in practice for the formulation of pharmaceutical preparations, which are required to have a rapid onset. It is evident from the curves that the tablets dissolve much more quickly than the ordered mixture alone. This is assumed to be because carrier particles are fragmented when the mixture is compacted into tablet form, such as to expose uncoated surfaces to the dissolving effect of the water present. The non-fragmented particles, on the other hand, are covered completely with a coating of not-readily dissolved active substance, which prevents the access of water to the soluble carrier.
• Example 2 This example illustrates the preparation of an ordered mixture in accordance with the invention and its formaulation into tablets.
• a batch of 100 tablets was produced from the following compositions: 36.5 g of mannitol and 1.92 g of Ac-Di-Sol R were mixed with about 170 ml of absolute etbanol. The mixture was dried and forced through a sieve of 1 mm mesh width, and the resultant fraction of particle size between 250 and 450 microns was mixed with 500 mg of micronized oxazepam, which had a specific surface area of not less than 20000 cm 2 /gm and with 0.1 g of finely ground mannitol, over a period of 50 hrs. The amount of oxazepam included corresponded to a surface area ratio of 0,5. This mixture was then admixed with 2.00 g of Avicel R PH 101 and 0.78 g of
• This example illustrates bow the addition of a lubricant affects the dissolution rate of a tablet which contains an ordered mixture.
• Two types of carrier substance were investigated. The substances or materials used were mannitol, which will fragmentize, and sodium chloride, which will not fragmentize.
• the dissolution rate of each of the mixtures was then Investigated in accordance with U.S.P. XXI, the paddle method, at room temperature and a stirring speed of 100 rpm.
• Tablets were then produced from each of the ordered mixtures, by mixing these mixtures with 5% w/w Avicel R PH 101 and 2% w/w Ac-Di-Sol R for 30 mins.
• the ordered mixture that contained mannitol as the carrier substance was divided into two parts. 0.2% w/w magnesium stearate was added to one part and 1% w/w magnesium stearate to the other. 1% w/w magnesium stearate was added to the mixture containing sodium chloride.
• the three mixtures were re-mixed for 10 mins.
• the resultant mixtures were compacted into tablet form, each containing 2 mg of oxazepam, at a pressure of 200 MPa.
• the dissolution rate of these tablets was investigated in accordance with U.S.P. XXI, the paddle method, at room temperature and a stirring speed of 100 rpm.
• FIG. 3 The results of these investigations are presented in Figure 3.
• the figure shows that a drug which comprises an ordered mixture with mannitol as the carrier substance will dissolve very quickly.
• An addition of 0.2% w/w magnesium prior to compacting the mixture does not affect the dissolution rate of the tablet. This is assumed to be because the carrier substance fragmentizes to expose fresh surfaces which facilitate access of the solvent to the carrier.
• the drug does not dissolve quite so well when the amount of ma ⁇ nesium stearate included is increased to 1% w/w. This is assumed to be because the increase in lubricant has a more negative influence on the dissolution rate, possibly due to a lesser degree of fragmentization of mannitol.
• a drug which is composed of an. ordered mixture with sodium chloride as the carrier substance will also dissolve quickly.
• the dissolution rate is impaired very considerably, when 1% w/w magnesium stearate is added prior to compaction. This is presumed to be because sodium chloride is not fragmentized during compaction, therewith rendering access of the solvent to the carrier difficult.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=20371045

Family Applications (2)

Family Applications After (1)

Country Status (6)

Families Citing this family (14)

• 1988
  • 1988-01-13 SE SE8800080A patent/SE8800080L/ unknown
• 1989
  • 1989-01-12 EP EP89901326A patent/EP0396599A1/de active Pending
  • 1989-01-12 WO PCT/SE1989/000008 patent/WO1989006533A1/en not_active Application Discontinuation
  • 1989-01-12 AU AU29233/89A patent/AU2923389A/en not_active Abandoned
  • 1989-01-12 DE DE89850006T patent/DE68905613T2/de not_active Expired - Lifetime
  • 1989-01-12 EP EP89850006A patent/EP0324725B1/de not_active Expired - Lifetime
  • 1989-01-12 AT AT89850006T patent/ATE87467T1/de not_active IP Right Cessation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events